DeepMed Research

Santen SAS

🇫🇷France

Country: 🇫🇷France

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.santen.eu/fr

Clinical Trials

Observational Survey Study on the Impact of Myopia and Its Complications on Quality of Life.

Not yet recruiting

Conditions: Myopia

First Posted Date: 2025-04-06

Last Posted Date: 2025-05-18

Lead Sponsor: Santen SAS

Target Recruit Count: 350

Registration Number: NCT06912802

LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis.

Phase 3

Recruiting

Conditions: Acquired Blepharophimosis

Interventions: Drug: STN1013800 (0.1% Oxymetazoline Hydrochloride) eye drops in single dose containers
Other: Placebo (0% Oxymetazoline Hydrochloride) eye drops in single dose containers

First Posted Date: 2024-07-23

Last Posted Date: 2025-03-20

Lead Sponsor: Santen SAS

Target Recruit Count: 234

Registration Number: NCT06514612

Locations: 🇵🇱
Profesorskie Centrum Okulistyki OKULISTYKA OPTIMUM, Gdańsk, Poland
🇵🇱
Gabinet Okulistyczny Prof. Edward Wylegala, Katowice, Poland
🇨🇿
Oftex.s.r.o, oční klinika, Pardubice, Czechia

and more 34 locations

3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis

Not Applicable

Completed

Conditions: Dry Eye Syndromes

Interventions: Device: Cationorm Pro
Device: Vismed

First Posted Date: 2021-01-08

Last Posted Date: 2025-05-21

Lead Sponsor: Santen SAS

Target Recruit Count: 83

Registration Number: NCT04701086

Locations: 🇫🇷
CHRU Bretonneau, Tours, France
🇵🇱
Gabinet Okulistyczny, Bielsko-Biala, Poland
🇵🇱
Szpital SW. Rozy, Krakow, Poland

and more 5 locations

3 Month Study of Alocross Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis

Not Applicable

Active, not recruiting

Conditions: Dry Eye Syndromes

Interventions: Device: Alocross 0.2% Unit Dose
Device: Vismed

First Posted Date: 2020-12-28

Last Posted Date: 2025-05-21

Lead Sponsor: Santen SAS

Target Recruit Count: 80

Registration Number: NCT04685109

Locations: 🇫🇷
Chru Brest Hopital Morvan, Brest, France
🇫🇷
Cabinet Liberal, La Rochefoucauld, France
🇫🇷
Hopital Edouard Herriot - Pavillon C, Lyon, France

and more 3 locations

3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)

Phase 3

Completed

Conditions: Dry Eye Disease With Severe Keratitis

Interventions: Drug: Masked Ikervis
Drug: Open-label Ikervis

First Posted Date: 2019-10-30

Last Posted Date: 2024-08-28

Lead Sponsor: Santen SAS

Target Recruit Count: 350

Registration Number: NCT04144413

Locations: 🇫🇷
Hopitaux Universitaires Paris-Sud - Hopital Bicetre, Le Kremlin-Bicêtre, Île-de-France, France
🇫🇷
Hôpital des Quinze-Vingts, Paris, Île-de-France, France
🇫🇷
Hopitaux Universitaires Paris Nord Val de Seine - Hopital Bichat - Claude Bernard, Paris, Île-de-France, France

and more 42 locations

A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Ocular Surface Disease
Open-Angle Glaucoma or Ocular Hypertension

Interventions: Drug: DE-130A
Drug: Xalatan®
Drug: DE-130A/DE-130A
Drug: Xalatan®/DE-130A

First Posted Date: 2019-10-21

Last Posted Date: 2024-05-28

Lead Sponsor: Santen SAS

Target Recruit Count: 386

Registration Number: NCT04133311

Locations: 🇫🇷
Hôpital des XV-XX, Paris, Île-de-France, France

Effect of IKERVIS® Eye Drops Once Daily on the Quality of Vision in Dry Eye Disease Patients With Severe Keratitis

Phase 4

Completed

Conditions: Keratitis

Interventions: Drug: 1mg/mL ciclosporin

First Posted Date: 2017-08-03

Last Posted Date: 2024-04-18

Lead Sponsor: Santen SAS

Target Recruit Count: 17

Registration Number: NCT03237936

Locations: 🇫🇷
CHU de Brest, Brest, France

Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis

Phase 3

Completed

Conditions: Vernal Keratoconjunctivitis

Interventions: Drug: Placebo
Drug: NOVA22007 ''Ciclosporin''

First Posted Date: 2012-12-17

Last Posted Date: 2022-03-28

Lead Sponsor: Santen SAS

Target Recruit Count: 169

Registration Number: NCT01751126

Locations: 🇺🇸
Glendale, CA, USA, Glendale, California, United States
🇺🇸
Rancho Cordova, CA, USA, Rancho Cordova, California, United States
🇬🇷
Thessaloniki, Macedonia, GR, Thessaloniki, Macedonia, Greece

and more 40 locations

Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease

Phase 2

Completed

Conditions: Ocular Surface Disease
Glaucoma
Ocular Hypertension

Interventions: Drug: Latanoprost
Drug: Travatan Z

First Posted Date: 2010-12-06

Last Posted Date: 2016-06-06

Lead Sponsor: Santen SAS

Target Recruit Count: 105

Registration Number: NCT01254370

Locations: 🇺🇸
Ora (Ophthalmic Research Associates), Andover, Massachusetts, United States

Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Versus Vehicle in Patients With Moderate to Severe Dry Eye Syndrome

Phase 3

Completed

Conditions: Moderate to Severe Dry Eye Syndrome

Interventions: Drug: NOVA22007
Drug: NOVA22007 (Ciclosporin 0.1%)

First Posted Date: 2008-12-25

Last Posted Date: 2010-07-16

Lead Sponsor: Santen SAS

Target Recruit Count: 482

Registration Number: NCT00814515

Locations: 🇫🇷
Hôpital des XV-XX, Paris, Île-de-France, France

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy